Actuate Therapeutics Inc(ACTU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ACTU Actuate Therapeutics Inc

盘前交易 09-30 06:42:32 EDT

0.6860

-0.0502

-6.82%

最高0.7479	最低0.6832	成交量11.28万
今开0.7380	昨收0.7362	日振幅8.79%
总市值1,641万	流通市值590.23万	总股本2,393万
成交额8.03万	换手率1.31%	流通股本860.40万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ACTU","market":"US","secType":"STK","nameCN":"Actuate Therapeutics Inc","latestPrice":0.686,"timestamp":1790712000000,"preClose":0.7362,"halted":0,"volume":112757,"delay":0,"changeRate":-0.06818799239337126,"floatShares":8604000,"shares":23925852,"eps":-0.885897,"marketStatus":"盘前交易","change":-0.0502,"latestTime":"09-30 06:42:32 EDT","open":0.738,"high":0.7479,"low":0.68321,"amount":80282.07856129,"amplitude":0.08787,"askPrice":0.8474,"askSize":100,"bidPrice":0.578,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.885897,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790775000000},"marketStatusCode":1,"adr":0,"listingDate":1723521600000,"exchange":"NASDAQ","adjPreClose":0.686,"postHourTrading":{"tag":"盘后","latestPrice":0.74053,"preClose":0.686,"latestTime":"19:58 EDT","volume":5209,"amount":3673.0803,"timestamp":1790726293472,"change":0.05453,"changeRate":0.07949,"amplitude":0.07949},"volumeRatio":0.4193836578293343},"requestUrl":"/m/hq/s/ACTU","defaultTab":"news","newsList":[{"id":"1193881960","title":"Actuate披露振奋人心的临床前数据：Elraglusib联合Ras抑制剂Zoldonrasib与Daraxonrasib展现协同抗肿瘤活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1193881960","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193881960?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:06","pubTimestamp":1788951974,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics公布了一系列令人瞩目的临床前研究结果，揭示其主打候选药物Elraglusib在与两款Ras抑制剂——Zoldonrasib及Daraxonrasib联合使用时，呈现出显著的协同增效作用。研究显示，当Elraglusib与上述Ras抑制剂搭配给药时，其抗肿瘤效果远超单药方案。具体而言，Elraglusib作为一款糖原合成酶激酶-3beta抑制剂，其作用机制与Ras抑制剂的靶向路径形成巧妙互补。Actuate管理层对这批数据寄予厚望，认为其不仅验证了Elraglusib的联合用药潜力，更为后续临床开发指明了清晰方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125886661","title":"Actuate Therapeutics旗下Elraglusib获选用于Beacon2高风险小儿神经母细胞瘤试验评估","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886661","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125886661?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:46","pubTimestamp":1781005576,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics旗下药物Elraglusib已被选中，将在Beacon2临床试验中接受评估，用于治疗高风险小儿神经母细胞瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154214300","title":"Actuate Therapeutics公布ASCO海报展示，揭示Elraglusib一线治疗转移性胰腺癌的强劲临床及生物标志物数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1154214300","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154214300?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:01","pubTimestamp":1780311678,"startTime":"0","endTime":"0","summary":"生物制药公司Actuate Therapeutics Inc宣布，其候选药物Elraglusib在一线治疗转移性胰腺癌的临床研究中，获得了令人瞩目的临床疗效与生物标志物数据，相关成果将在美国临床肿瘤学会年会上以海报形式进行展示。此次公布的数据进一步证实了Elraglusib在治疗这一难治性癌症方面的潜力。胰腺癌，尤其是转移性胰腺癌，长期以来缺乏有效的治疗手段，患者预后极差。Elraglusib的新数据为这一领域带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187375862","title":"Actuate Therapeutics Inc：FDA批准口服Elraglusib用于晚期癌症患者的1/2期研究新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1187375862","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187375862?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:01","pubTimestamp":1778497280,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics Inc宣布，美国食品药品监督管理局（FDA）已批准其口服药物Elraglusib用于治疗晚期癌症患者的新药临床试验申请，该申请旨在启动一项1/2期临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107661115","title":"Actuate Therapeutics宣布口服Elraglusib新药临床试验申请获FDA批准，并公布推进其研发项目的战略举措","url":"https://stock-news.laohu8.com/highlight/detail?id=1107661115","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107661115?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:01","pubTimestamp":1778497278,"startTime":"0","endTime":"0","summary":"Actuate Therapeutics公司今日宣布，其口服Elraglusib的新药临床试验申请已获得美国食品药品监督管理局的批准。与此同时，公司还公布了一系列旨在加速Elraglusib研发项目的战略性举措。\n这一监管进展标志着Elraglusib的开发进入了新的阶段。获得FDA的临床试验许可，使得公司能够启动针对该口服制剂的研究，进一步探索其在相关适应症中的潜力。\n除了监管层面的突破，Actuate Therapeutics也同步启动了多项战略计划，以全面推动Elraglusib项目的进展。这些举措旨在优化开发路径，整合资源，并加速该候选药物从临床研究向潜在商业化迈进的步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149138255","title":"Actuate Therapeutics任命行业资深人士Martin Huber博士为独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1149138255","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149138255?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:47","pubTimestamp":1778071646,"startTime":"0","endTime":"0","summary":"芝加哥和德克萨斯州沃思堡——临床阶段生物制药公司Actuate Therapeutics Inc 今日宣布，任命医学博士Martin Huber为董事会独立董事，该任命立即生效。此次人事变动将强化公司领导团队实力，正值其核心候选药物elraglusib针对多种难治性癌症适应症向注册研究和商业化阶段推进的关键时期。Actuate Therapeutics总裁兼首席执行官Daniel Schmitt表示：\"我们非常荣幸欢迎Marty加入董事会。Huber博士近期曾担任Mersana Therapeutics总裁兼首席执行官，直至该公司于2026年1月被Day One Pharmaceuticals收购。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518627975","title":"Actuate Therapeutics, Inc.盘中异动 急速拉升6.12%报7.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518627975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518627975?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:33","pubTimestamp":1741613586,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时33分，Actuate Therapeutics, Inc.股票出现波动，股价大幅拉升6.12%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2057.25%、403.96%、61.18%，振幅较大的相关个股有Akero Therapeutics, Inc.、Xencor, Inc.、Seer, Inc.，振幅分别为99.91%、99.13%、98.72%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021330796403636&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021330796403636&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517937811","title":"Actuate Therapeutics, Inc.盘中异动 快速下挫5.29%报6.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517937811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517937811?lang=zh_cn&edition=full","pubTime":"2025-03-07 01:29","pubTimestamp":1741282156,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日01时29分，Actuate Therapeutics, Inc.股票出现波动，股价急速跳水5.29%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.77%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307012917963c6d1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307012917963c6d1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ACTU","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516673655","title":"Actuate Therapeutics, Inc.盘中异动 临近午盘急速下跌9.21%报6.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516673655","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516673655?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:31","pubTimestamp":1741019501,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时31分，Actuate Therapeutics, Inc.股票出现波动，股价快速下挫9.21%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.27%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003141abe6593c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003141abe6593c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514869643","title":"Actuate Therapeutics, Inc.盘中异动 股价大涨9.30%报7.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869643","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514869643?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:48","pubTimestamp":1740667706,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时48分，Actuate Therapeutics, Inc.股票出现异动，股价大幅上涨9.30%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722482798951393&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722482798951393&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514568488","title":"Actuate Therapeutics, Inc.盘中异动 股价大涨7.72%报7.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514568488","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514568488?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:38","pubTimestamp":1740580701,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时38分，Actuate Therapeutics, Inc.股票出现波动，股价急速拉升7.72%。截至发稿，该股报7.61美元/股，成交量768股，换手率0.00%，振幅0.00%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.57%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223821a254f84e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223821a254f84e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513361778","title":"Actuate Therapeutics, Inc.盘中异动 大幅下挫5.16%报7.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513361778","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513361778?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:07","pubTimestamp":1740409622,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时07分，Actuate Therapeutics, Inc.股票出现异动，股价快速下挫5.16%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Pepgen Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为165.25%、72.03%、25.97%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230702a2521d54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230702a2521d54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511669733","title":"Actuate Therapeutics, Inc.盘中异动 早盘急速跳水5.56%报7.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511669733","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511669733?lang=zh_cn&edition=full","pubTime":"2025-02-14 23:53","pubTimestamp":1739548389,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日23时53分，Actuate Therapeutics, Inc.股票出现异动，股价急速下跌5.56%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.76%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021423530998859cd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021423530998859cd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510360403","title":"Actuate Therapeutics, Inc.盘中异动 早盘急速跳水5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510360403","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510360403?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:56","pubTimestamp":1739289410,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时56分，Actuate Therapeutics, Inc.股票出现波动，股价快速跳水5.94%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.77%。其相关个股中，Ocean Biomedical, Inc.、Lipella Pharmaceuticals Inc.、Dominari Holdings Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2752.22%、1190.45%、390.00%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为58.60%、57.43%、40.87%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211235650a2420e2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211235650a2420e2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508140788","title":"Actuate Therapeutics, Inc.盘中异动 早盘大幅拉升5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508140788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508140788?lang=zh_cn&edition=full","pubTime":"2025-02-04 00:10","pubTimestamp":1738599013,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日00时10分，Actuate Therapeutics, Inc.股票出现异动，股价急速上涨5.32%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Invivyd, Inc.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为576.67%、440.17%、362.89%，振幅较大的相关个股有Hcw Biologics Inc.、Invivyd, Inc.、Briacell Therapeutics Corp.，振幅分别为167.11%、75.23%、63.65%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204001013a2381df3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204001013a2381df3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507770961","title":"Actuate Therapeutics, Inc.盘中异动 早盘急速拉升7.36%报9.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507770961","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507770961?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:39","pubTimestamp":1738337967,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时39分，Actuate Therapeutics, Inc.股票出现异动，股价快速拉升7.36%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.15%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131233927a2354f37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131233927a2354f37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506306476","title":"Actuate Therapeutics, Inc.盘中异动 早盘股价大涨6.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506306476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506306476?lang=zh_cn&edition=full","pubTime":"2025-01-27 23:18","pubTimestamp":1737991096,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日23时18分，Actuate Therapeutics, Inc.股票出现异动，股价急速拉升6.82%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.99%。其相关个股中，Akero Therapeutics, Inc.、Onconetix, Inc.、89Bio, Inc.涨幅较大，Onconetix, Inc.、Evaxion Biotech As、Dogwood Therapeutics, Inc.较为活跃，换手率分别为1735.73%、191.22%、170.94%，振幅较大的相关个股有Onconetix, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Immatics N V C/Wts 01/07/2025 ，振幅分别为85.35%、65.16%、61.25%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127231816a231749c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127231816a231749c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505869022","title":"Actuate Therapeutics, Inc.盘中异动 早盘股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505869022","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505869022?lang=zh_cn&edition=full","pubTime":"2025-01-24 22:36","pubTimestamp":1737729360,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日22时36分，Actuate Therapeutics, Inc.股票出现波动，股价大幅跳水5.09%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124223600abb74f92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124223600abb74f92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ACTU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505277440","title":"Actuate Therapeutics, Inc.盘中异动 下午盘股价大涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505277440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505277440?lang=zh_cn&edition=full","pubTime":"2025-01-23 02:32","pubTimestamp":1737570762,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日02时32分，Actuate Therapeutics, Inc.股票出现波动，股价快速拉升5.61%。Actuate Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Actuate Therapeutics, Inc.公司简介：Actuate Therapeutics Inc是一家临床阶段的生物制药公司，专注于通过抑制糖原合酶激酶3 来开发治疗高影响的、难治的癌症的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123023243abb4d6e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123023243abb4d6e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ACTU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.actuatetherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1504},{"period":"1month","weight":-0.5855},{"period":"3month","weight":-0.5236},{"period":"6month","weight":-0.7234},{"period":"1year","weight":-0.8987},{"period":"ytd","weight":-0.8879}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0247},{"period":"6month","weight":0.1652},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.1207}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Actuate Therapeutics, Inc.是一家成立于2015年1月16日的特拉华州公司。该公司是一家临床阶段的生物制药公司，专注于通过抑制糖原合成酶激酶-3（GSK-3）开发治疗高影响、难以治疗的癌症的疗法。他们正在开发elraglusib（前身为9-ING-41），这是一种小分子，旨在进入癌症细胞并阻断GSK-3β酶的功能，GSK-3是复杂生物信号级联的主要调节因子，包括致癌基因介导的信号级联，导致肿瘤细胞存活、生长、迁移和侵袭。","exchange":"NASDAQ","name":"Actuate Therapeutics Inc","nameEN":"Actuate Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Actuate Therapeutics Inc(ACTU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Actuate Therapeutics Inc(ACTU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Actuate Therapeutics Inc,ACTU,Actuate Therapeutics Inc股票,Actuate Therapeutics Inc股票老虎,Actuate Therapeutics Inc股票老虎国际,Actuate Therapeutics Inc行情,Actuate Therapeutics Inc股票行情,Actuate Therapeutics Inc股价,Actuate Therapeutics Inc股市,Actuate Therapeutics Inc股票价格,Actuate Therapeutics Inc股票交易,Actuate Therapeutics Inc股票购买,Actuate Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Actuate Therapeutics Inc(ACTU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Actuate Therapeutics Inc(ACTU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}